leadf
logo-loader
viewFSD Pharma
(
CSE:HUGENASDAQ:HUGE
)

FSD Pharma fully funded to continue progress on its Phase 2 study on coronavirus patients

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE.CN) CEO Raza Bokhari tells Proactive the biopharma group is fully funded to continue progress on its Phase 2 study to treat hospitalized coronavirus patients.

Bokhari says its most recent fundraising gives the firm $9.5M to conduct the trial, which will begin dosing patients in the next couple of weeks. Despite a recent decline in share price, Bokhari says the group is in execution mode, and has delivered more milestones ahead of schedule.

Quick facts: FSD Pharma

Follow
CSE:HUGE

Price: 1.9 CAD

Market Cap: $68.09 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

FSD Pharma 'excited' to acquire pharma group Lucid Psycheceuticals to...

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc (CSE:HUGE) (NASDAQ:HUGE) Interim CEO Anthony Durkacz tells Proactive the group is to buy Canada-based specialty psychedelic pharma group Lucid Psycheceuticals Inc in a stock deal worth around US$9 million (C$11.3 million). Durkacz says the life sciences...

4 weeks ago

2 min read